Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Health Services industry as a whole closed the day down 1.8% versus the S&P 500, which was down 1.3%. Laggards within the Health Services industry included Signal Genetics ( SGNL), down 3.1%, Huttig Building Products ( HBP), down 3.5%, Vision-Sciences ( VSCI), down 4.1%, USMD Holdings ( USMD), down 5.4% and BioLife Solutions ( BLFS), down 2.8%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today:

Align Technology ( ALGN) is one of the companies that pushed the Health Services industry lower today. Align Technology was down $5.62 (9.6%) to $53.05 on heavy volume. Throughout the day, 5,109,473 shares of Align Technology exchanged hands as compared to its average daily volume of 670,900 shares. The stock ranged in price between $51.77-$55.15 after having opened the day at $52.79 as compared to the previous trading day's close of $58.67.

Align Technology, Inc. operates as a medical device company primarily in the United States and internationally. Align Technology has a market cap of $4.7 billion and is part of the health care sector. Shares are up 4.9% year-to-date as of the close of trading on Thursday. Currently there are 7 analysts who rate Align Technology a buy, no analysts rate it a sell, and 1 rates it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Align Technology as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

Highlights from TheStreet Ratings analysis on ALGN go as follows:

  • The revenue growth came in higher than the industry average of 4.6%. Since the same quarter one year prior, revenues rose by 15.4%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • ALGN has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 2.80, which clearly demonstrates the ability to cover short-term cash needs.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, ALIGN TECHNOLOGY INC's return on equity exceeds that of both the industry average and the S&P 500.
  • The gross profit margin for ALIGN TECHNOLOGY INC is currently very high, coming in at 78.57%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 20.14% is above that of the industry average.
  • Net operating cash flow has increased to $67.57 million or 22.54% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of -18.13%.

You can view the full analysis from the report here: Align Technology Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, BioLife Solutions ( BLFS) was down $0.05 (2.8%) to $1.77 on average volume. Throughout the day, 30,956 shares of BioLife Solutions exchanged hands as compared to its average daily volume of 36,000 shares. The stock ranged in price between $1.71-$1.83 after having opened the day at $1.83 as compared to the previous trading day's close of $1.82.

BioLife Solutions, Inc. develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues. BioLife Solutions has a market cap of $21.8 million and is part of the health care sector. Shares are up 11.0% year-to-date as of the close of trading on Thursday. Currently there are 2 analysts who rate BioLife Solutions a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates BioLife Solutions as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share.

Highlights from TheStreet Ratings analysis on BLFS go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 178.1% when compared to the same quarter one year ago, falling from -$0.31 million to -$0.86 million.
  • Net operating cash flow has significantly decreased to -$0.70 million or 5716.66% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • BIOLIFE SOLUTIONS INC's earnings have gone downhill when comparing its most recently reported quarter with the same quarter a year earlier. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, BIOLIFE SOLUTIONS INC continued to lose money by earning -$0.14 versus -$0.42 in the prior year. For the next year, the market is expecting a contraction of 121.4% in earnings (-$0.31 versus -$0.14).
  • This stock's share value has moved by only 78.38% over the past year. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The revenue fell significantly faster than the industry average of 4.6%. Since the same quarter one year prior, revenues fell by 42.7%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.

You can view the full analysis from the report here: BioLife Solutions Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Vision-Sciences ( VSCI) was another company that pushed the Health Services industry lower today. Vision-Sciences was down $0.02 (4.1%) to $0.47 on heavy volume. Throughout the day, 130,051 shares of Vision-Sciences exchanged hands as compared to its average daily volume of 44,300 shares. The stock ranged in price between $0.47-$0.50 after having opened the day at $0.48 as compared to the previous trading day's close of $0.49.

Vision-Sciences, Inc., through its subsidiaries, designs, develops, manufactures, and markets endoscopy products. It operates through Medical and Industrial segments. Vision-Sciences has a market cap of $23.7 million and is part of the health care sector. Shares are down 31.0% year-to-date as of the close of trading on Thursday.

TheStreet Ratings rates Vision-Sciences as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins and generally disappointing historical performance in the stock itself.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on VSCI go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed against the S&P 500 and did not exceed that of the Health Care Equipment & Supplies industry. The net income has decreased by 16.6% when compared to the same quarter one year ago, dropping from -$1.32 million to -$1.54 million.
  • The gross profit margin for VISION-SCIENCES INC is currently lower than what is desirable, coming in at 34.31%. It has decreased from the same quarter the previous year. Along with this, the net profit margin of -37.54% is significantly below that of the industry average.
  • VSCI's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 59.69%, which is also worse than the performance of the S&P 500 Index. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • VISION-SCIENCES INC reported flat earnings per share in the most recent quarter. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, VISION-SCIENCES INC continued to lose money by earning -$0.16 versus -$0.22 in the prior year.
  • Despite its growing revenue, the company underperformed as compared with the industry average of 4.6%. Since the same quarter one year prior, revenues slightly increased by 3.6%. This growth in revenue does not appear to have trickled down to the company's bottom line, displaying stagnant earnings per share.

You can view the full analysis from the report here: Vision-Sciences Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.